BioXcel Therapeutics (BTAI) Misses Q2 EPS by 245c

BioXcel Therapeutics (NASDAQ: BTAI) reported Q2 EPS of ($2.45). Revenue for the quarter came in at $120 thousand.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

You May Also Be Interested In

• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
• S&P Global US Manufacturing PMI (Jun P) 55.7 vs 54.6 Expected
• Simulations Plus uses Nvidia BioNeMo toolkit for drug development AI